Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated September 5, 2024, serves as a notice to shareholders regarding a clarification to the Proxy Statement for the Annual General Meeting of Shareholders scheduled for September 17, 2024. The filing addresses the impact of a recent American Depositary Share (ADS) ratio change on proposed Restricted Share Unit (RSU) grants.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notice and does not contain financial performance data.
Material Changes
- ADS Ratio Change: On August 16, 2024, the Company announced a change in the ADS to ordinary share ratio from 1:400 to 1:10,000, effective August 20, 2024. This is equivalent to a one-for-25 reverse ADS split.
- Proxy Statement Clarification: Proposals 3, 4, and 5 in the previously filed Proxy Statement regarding RSU grants to directors and executives must be adjusted to reflect the new ratio. All references to ADS numbers in these proposals are deemed divided by 25.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on business operations. The primary focus is the administrative correction of share counts for upcoming shareholder votes. No specific risks or contingencies are detailed beyond the procedural necessity of the clarification.
Key Facts for Investor Verification
- Adjusted RSU Grants: Verify the updated RSU counts for the Annual Meeting proposals:
- Proposal 3 (Non-executive directors): Dr. Shmuel Cabilly and Dr. Kenneth Reed (1,360 ADSs each), Mr. Eric Swenden (1,520 ADSs), Mr. Ofer Tsimchi (2,000 ADSs).
- Proposal 4 (CEO Dror Ben-Asher): 5,080 ADSs.
- Proposal 5 (CCO Rick D. Scruggs): 4,000 ADSs.
- Meeting Date: The Annual General Meeting is scheduled for September 17, 2024.
- Effective Date of Split: The 1-for-25 reverse ADS split effect became effective on August 20, 2024.